PUBLISHED MANUSCRIPTS
(updated July 2026)
- Fernandez HH, et al. (2026) Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson’s disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial. Lancet Neurol. DOI: 10.1016/S1474-4422(26)00215-2
- Pahwa R, et al. (2026) Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol, 83(5), 452-460. DOI: 10.1001/jamaneurol.2026.0590
- Fernandez HH, et al. (2026) Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial. JAMA Neurol, 83(5), 442-451. DOI: 10.1001/jamaneurol.2026.0577
- Al Hadidi S, et al. (2026) Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection. Clin Lymphoma Myeloma Leuk, 26(6), e752-e766. DOI: 10.1016/j.clml.2026.03.009
- Ailawadhi S, et al. (2025) Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable. Clin Lymphoma Myeloma Leuk, 26(2), 85-93. DOI: 10.1016/j.clml.2025.08.005
- Hansen DK, et al. (2025) Patient and caregiver perspectives on treatment decision-making for stem cell transplantation in multiple myeloma. Support Care Cancer, 33(2), 134. DOI: 10.1007/s00520-025-09195-1
- San-Miguel J, et al. (2024) Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma. Future Oncol, 20(33), 2509-2520. DOI: 10.1080/14796694.2024.2376973
- Provided writing oversight on initial draft and served as lead writer on subsequent drafts
- Gadsden J, Gonzales J, Chen A. (2024) Relationship between injectate volume and disposition in erector spinae plane block: a cadaveric study. Reg Anesth Pain Med, 49(7), 511-517. DOI: 10.1136/rapm-2023-104717
- Ailawadhi S, et al. (2024) Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable. Clin Lymphoma Myeloma Leuk, 24(5), e217-e225. DOI: 10.1016/j.clml.2024.01.014
- Bezard E, et al. (2024) Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson’s Disease. CNS Neurol Disord Drug Targets, 23(4), 476-487. DOI: 10.2174/1871527322666230331121028
- Steinbach M, et al. (2023) Nursing Care Throughout the Chimeric Antigen Receptor T-Cell Therapy Process for Multiple Myeloma. Semin Oncol Nurs, 39(6), 151505. DOI: 10.1016/j.soncn.2023.151505
- Isaacson SH, et al. (2023) Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. Clin Park Relat Disord, 9, 100212. DOI: 10.1016/j.prdoa.2023.100212
- Berdeja JG, et al. (2023) Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma. Future Oncol, 19(18), 1235-1247. DOI: 10.2217/fon-2023-0270
